Abstract 1535
Background
EGFR mutation is the major driver mutation in East Asian lung cancer. By and large, this group of lung cancer patients has a better prognosis in advanced stage pulmonary adenocarcinoma. However, the prognostic role of these sensitizing EGFR mutations in early stage is uncertain. We aimed to investigate the prognostic value of EGFR mutation and other factors for tumor recurrence in completely resected LNNPA.
Methods
We recruited 220 patients with LNNPA who were diagnosed and treated at the King Chulalongkorn Memorial Hospital from January 1, 2009 to December 31, 2016. Recurrence included pathological diagnosis, imaging confirmations, or death. Recurrence-free survival was analyzed by univariable and multivariable Cox regression analyses.
Results
Median follow up time was 4 (2.7-5.6) years. There were more female (62%), never smokers (68%), stage I (86%) and EGFR mutations (54%). The most common EGFR mutations were exon 19 deletion (51%) and L858R (43%). Most patients did not receive adjuvant treatment (85.6%). There were 60 out of 220 (27.3%) patients had recurrent disease. The median time to recurrence was 2.3 years. The rate of loco-regional, distant and both types of recurrence were 27%, 68% and 5% respectively. Univariate analysis revealed smoking ≥ 10 pack-year, performance status ≥ 2, tumor size ≥ 4 cm, histologic grade ≥ 2, lymphovascular invasion, visceral pleural invasion, tumor necrosis and bronchial resection margin (BRM) < 2 cm were significant prognostic factors for tumor recurrence. However, tumor size ≥ 4 cm, visceral pleural invasion, tumor necrosis and BRM < 2 cm remained the significant prognostic factors with multivariate analysis (Table). Sensitizing EGFR mutation was not a significant prognostic factor in this cohort by both univariate and multivariate analyses.Table: 1451P
Multivariate analysis
Covariate | HR | 95% CI | P-value |
---|---|---|---|
Tumor size ≥ 4 cm | 1.96 | 1.1 - 3.6 | 0.03 |
Visceral Pleural invasion | 2.38 | 1.3 - 4.3 | 0.004 |
< 2 cm of bronchial resection margin | 2.48 | 1.4 - 4.3 | 0.002 |
Tumor necrosis | 3.12 | 1.7 - 5.6 | < 0.001 |
EGFR mutation | 1.23 | 0.6 - 2.7 | 0.57 |
Conclusions
Among Thai, East Asian, early stage lung cancer, sensitizing EGFR mutation has similar outcomes to those without EGFR mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ratchadapisek Sompoch Endowment Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract